ZA991572B - New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide. - Google Patents

New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.

Info

Publication number
ZA991572B
ZA991572B ZA9901572A ZA991572A ZA991572B ZA 991572 B ZA991572 B ZA 991572B ZA 9901572 A ZA9901572 A ZA 9901572A ZA 991572 A ZA991572 A ZA 991572A ZA 991572 B ZA991572 B ZA 991572B
Authority
ZA
South Africa
Prior art keywords
methyl
methylcarbamoyl
phenylethyl
naphthyl
amide
Prior art date
Application number
ZA9901572A
Other languages
English (en)
Inventor
Claus Ulrich Jessen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA991572B publication Critical patent/ZA991572B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA9901572A 1998-03-03 1999-02-26 New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide. ZA991572B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK28298 1998-03-03

Publications (1)

Publication Number Publication Date
ZA991572B true ZA991572B (en) 1999-09-03

Family

ID=8091813

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901572A ZA991572B (en) 1998-03-03 1999-02-26 New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.

Country Status (15)

Country Link
EP (1) EP1060190B1 (xx)
JP (1) JP2002505340A (xx)
KR (1) KR20010041533A (xx)
CN (1) CN1291994A (xx)
AT (1) ATE254632T1 (xx)
AU (1) AU3247899A (xx)
BR (1) BR9908399A (xx)
CA (1) CA2322051A1 (xx)
DE (1) DE69912930D1 (xx)
HU (1) HUP0100998A3 (xx)
IL (1) IL137353A0 (xx)
PL (1) PL342706A1 (xx)
TW (1) TW538047B (xx)
WO (1) WO1999045029A1 (xx)
ZA (1) ZA991572B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US10023600B2 (en) 2009-09-21 2018-07-17 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CA2972592A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
AU2018235754B2 (en) 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
CN115666570A (zh) 2020-05-29 2023-01-31 吉利德科学公司 瑞德西韦治疗方法
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CA3190702A1 (en) 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323159T3 (es) * 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.

Also Published As

Publication number Publication date
WO1999045029A1 (en) 1999-09-10
CN1291994A (zh) 2001-04-18
HUP0100998A3 (en) 2001-12-28
IL137353A0 (en) 2001-07-24
JP2002505340A (ja) 2002-02-19
EP1060190A1 (en) 2000-12-20
ATE254632T1 (de) 2003-12-15
EP1060190B1 (en) 2003-11-19
PL342706A1 (en) 2001-07-02
HUP0100998A2 (hu) 2001-08-28
DE69912930D1 (de) 2003-12-24
TW538047B (en) 2003-06-21
KR20010041533A (ko) 2001-05-25
BR9908399A (pt) 2000-10-31
AU3247899A (en) 1999-09-20
CA2322051A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
ZA991572B (en) New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.
RS82003A (xx) Amidi antranilne kiseline, postupak za njihovu proizvodnju, njihova primena u svojstvu antiaritmijskih sredstava kao i farmaceutski preparati koji sadrže ta jedinjenja
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
WO2000055126A3 (en) N-cyanomethylamides as protease inhibitors
AU2003245804A1 (en) Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
PL309721A1 (en) Pharmaceutical composition containing fluoxetin hydrochloride
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
WO2002058692A3 (fr) Composition halogenee de hypohalites avec n-chloramine taurine, procede de preparation et ses utilisations
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
AU2001267886A1 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
MXPA03009984A (es) PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
DE60119976D1 (en) Thixotropes nasenspray
MY120237A (en) Method for the synthesis of quinoline derivatives
HUP0202324A2 (hu) Prukaloprid orális oldat
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2003017762A3 (de) Fungizide wirkstoffkombinationen
CA2429793A1 (en) Interferon therapeutic effect enhancer
MY122588A (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
PL352532A1 (en) New analogues: 2', 3'-dideoxy-3'fluorothymidyne active against the hiv-1 and hiv-2 viruses, the method of their manufacture, and pharmaceuticals containing them
AU3147800A (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
AU3147900A (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine